A case of bilateral uveitis in a patient treated with vemurafenib.
作者信息
Mehmet Aysel, Mikropoulou Athanasia Maria, Panagiotopoulou Eirini-Kanella, Konstantinidis Aristeidis, Labiris Georgios
机构信息
University Eye Clinic, University Hospital of Alexandroupolis, Greece.
出版信息
Oman J Ophthalmol. 2022 Nov 2;15(3):431-432. doi: 10.4103/ojo.ojo_240_21. eCollection 2022 Sep-Dec.
Abstract
摘要
相似文献
1
A case of bilateral uveitis in a patient treated with vemurafenib.一名接受维莫非尼治疗的患者发生双侧葡萄膜炎的病例。
Oman J Ophthalmol. 2022 Nov 2;15(3):431-432. doi: 10.4103/ojo.ojo_240_21. eCollection 2022 Sep-Dec.
2
Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib.维莫非尼治疗晚期皮肤黑色素瘤患者的葡萄膜炎。
JAMA Ophthalmol. 2014 Dec;132(12):1421-5. doi: 10.1001/jamaophthalmol.2014.3024.
3
Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma.由维莫非尼治疗转移性黑色素瘤引起的肉瘤样肉芽肿性眼内炎症。
Turk J Ophthalmol. 2020 Mar 5;50(1):50-52. doi: 10.4274/tjo.galenos.2019.79026.
4
Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma.患者在接受维莫非尼治疗转移性黑色素瘤时出现严重的全葡萄膜炎。
BMC Cancer. 2013 Dec 1;13:561. doi: 10.1186/1471-2407-13-561.
5
A Rare Cause of Uveitis: Vemurafenib.葡萄膜炎的一种罕见病因：维莫非尼
Turk J Ophthalmol. 2018 Dec 27;48(6):323-325. doi: 10.4274/tjo.95914.
6
Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.用维莫非尼治疗转移性黑色素瘤患者中的结节病：一种矛盾的自身免疫激活。
Dermatology. 2015;231(4):378-84. doi: 10.1159/000439400. Epub 2015 Oct 10.
7
[Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].[MEK抑制剂和BRAF抑制剂靶向治疗转移性皮肤黑色素瘤的眼部毒性]
J Fr Ophtalmol. 2022 Jun;45(6):612-618. doi: 10.1016/j.jfo.2021.08.005. Epub 2022 Apr 29.
8
Development of Acute Vogt-Koyanagi-Harada-like Syndrome during the Treatment Course with Vemurafenib for Metastatic Melanoma.维莫非尼治疗转移性黑色素瘤过程中出现急性 Vogt-Koyanagi-Harada 样综合征。
Ocul Immunol Inflamm. 2020 Apr 2;28(3):505-508. doi: 10.1080/09273948.2019.1597896. Epub 2019 Jun 4.
9
Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.使用维莫非尼治疗的BRAF突变型皮肤黑色素瘤患者的眼部毒性。
Am J Ophthalmol. 2014 Oct;158(4):831-837.e2. doi: 10.1016/j.ajo.2014.07.003. Epub 2014 Jul 15.
10
Uveitis associated with cancer immunotherapy: long-term outcomes.与癌症免疫治疗相关的葡萄膜炎：长期结局。
Immunotherapy. 2021 Dec;13(18):1465-1481. doi: 10.2217/imt-2021-0032. Epub 2021 Oct 28.
本文引用的文献
1
Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma.由维莫非尼治疗转移性黑色素瘤引起的肉瘤样肉芽肿性眼内炎症。
Turk J Ophthalmol. 2020 Mar 5;50(1):50-52. doi: 10.4274/tjo.galenos.2019.79026.
2
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.MEK抑制剂相关性视网膜病变的临床和形态学特征：与中心性浆液性脉络膜视网膜病变的差异
Ophthalmology. 2017 Dec;124(12):1788-1798. doi: 10.1016/j.ophtha.2017.05.038. Epub 2017 Jul 12.
3
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.联合维莫非尼和考比替尼治疗 BRAF 突变型黑色素瘤。
N Engl J Med. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29.
4
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.美国食品和药物管理局批准摘要：威罗菲尼用于治疗携带 BRAFV600E 突变的不可切除或转移性黑色素瘤。
Clin Cancer Res. 2014 Oct 1;20(19):4994-5000. doi: 10.1158/1078-0432.CCR-14-0776. Epub 2014 Aug 5.
5
Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.使用维莫非尼治疗的BRAF突变型皮肤黑色素瘤患者的眼部毒性。
Am J Ophthalmol. 2014 Oct;158(4):831-837.e2. doi: 10.1016/j.ajo.2014.07.003. Epub 2014 Jul 15.
Zotero 插件